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Xanthine oxidase (XOD) is an enzyme which plays a central role in purine catabolism by converting
hypoxanthine into xanthine and then further into uric acid. Here we report that XOD is activated in THP-1
human myeloid cells in response to pro-inflammatory and growth factor stimulation. This effect occurred
following stimulation of THP-1 cells with ligands of plasmamembrane associated TLRs 2 and 4, endosomal
TLRs 7 and 8 as well as stem cell growth factor (SCF). Hypoxia-inducible factor 1 (HIF-1) and activator
protein 1 (AP-1) transcription complexes were found to be responsible for XODupregulation. Importantly,
the mammalian target of rapamycin (mTOR), a major myeloid cell translation regulator, was also found to
be essential for XOD activation. Specific inhibition of XOD by allopurinol and sodium tungstate led to an
increase in intracellular AMP levels triggering downregulation of mTOR activation by phosphorylation of
its T2446 residue. Taken together, our results demonstrate for the first time that XOD is not only activated
by pro-inflammatory stimuli or SCF but also plays an important role in maintaining mTOR-dependent
translational control during the biological responses of human myeloid cells.
X
anthine oxidase (XOD), also known as xanthine oxidoreductase, is the enzyme which plays a central role in
purine catabolism by utilising biologically active nucleotides arising from the degradation of nucleic acids
and nucleotide mediators1. XOD has two inter-convertible isoforms – oxygen-dependent oxidase and
NAD1-dependent dehydrogenase. Both isoforms catalyse the conversion of hypoxanthine into xanthine and
then further into uric acid (UA), the two terminal reactions of purine degradation pathway in humans, primates
and birds. XOD is a homodimer (reported molecular weight – 283–290 KD) composed of two catalytically
independent subunits with an approximate molecular weight of 150–155 KD1,2. Each monomer contains 3
subunits with a mass of either 20, 40 or 85 KD, which can be separated from each other only under strong
denaturing conditions. Eachmonomer contains 2 iron-sulphur clusters (Fe2-S2, located in the 20 KD subunit), 1
flavin adenine dinucleotide molecule (FAD, located in the 40 KD subunit) and the molybdenum (Mo) cofactor
which is bound to the enzyme as molybdopterin (located in the 85 KD subunit). Each full-length (150 KD)
monomer displays catalytic activity but neither of the smaller fragments can catalyse the XOD reaction since all
the cofactors are required for the catalytic act1,2.
For almost 100 years XOD was known as a purine catabolising enzyme that generates UA, a poorly soluble
compound which may become accumulated in the synovial tissue3. While XOD was also recognised as a super-
oxide producer it was not considered as a main contributor to the cellular reactive oxygen species (ROS) pool4,
except the cases of reperfusion injury. Recently, increasing evidence suggests that XOD plays a role in the
biochemical regulation of myeloid cell function thus promoting their inflammatory state5. However, basic
biochemical mechanisms underlying the functional role of this enzyme in maintaining the functional control
of myeloid cell biological activity have not been elucidated. It was found that inflammatory stimuli like lipopo-
lysaccharide (LPS, toll-like receptor (TLR) 4 ligand), resiquimod (R848, endosomal TLR7/8 ligand), and cyto-
kines – tumour necrosis factor alpha, interleukin 1 beta (IL-1b), interleukin 6 (IL-6) and interferon c1,6,7 induce
XOD activation. Our recent findings demonstrated that XOD activity inmyeloid cells is required for TLR/ligand-
associated activation of the inflammasome, a multiprotein complex which catalyzes proteolytic reactions leading
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XOD activity has also been found to be increased under hypoxic
conditions, which often form a physiological environment for mye-
loid cell responses. We also found that the pro-inflammatory upre-
gulation of XOD activity in myeloid cells requires activation of the
hypoxia-inducible factor 1 (HIF-1) transcription complex, which
controls the adaptation of myeloid cells to signalling stress8–10. The
XOD gene promoter region (this gene contains .60 kb with 36
exons and is located in the short arm of human chromosome
2)1,11,12 contains two hypoxia-responsive elements (HIF-1 respons-
ive) and 5 elements responsive to the activator protein 1 (AP1)
transcription complex. Interestingly, a ligand/receptor-specific
cross-link between the activities of XOD and HIF-1 has also been
demonstrated6. Furthermore, XOD inhibitors were found to down-
regulate S2448 phosphorylation of the mammalian target of rapa-
mycin (mTOR), which is required for activation of this kinase and
plays a major role in the translational control of cellular responses
and is essential for myeloid cell function13. Downstream responses of
mTOR in myeloid cells could also be downregulated by XOD inhi-
bitors in myeloid leukaemia cells7,10.
Despite the above, there is, however, currently no clear evidence
regarding the mechanisms of XOD activation in myeloid cells at
either a transcriptional, translational or post-translational stage.
All three mechanisms or their combination appear possible in the
case of an enzyme such as XOD. Despite the evidence described, a
conceptual basic knowledge of the mechanisms of XOD activation
and its functional role is still almost absent. Here, we report that XOD
is indeed activated in human myeloid leukaemia cells in response to
pro-inflammatory and growth factor stimulation. This effect was
observed when treating the cells with ligands of plasma membrane
associated TLRs 2 and 4, endosomal TLRs 7 and 8 as well as stem cell
factor (SCF). HIF-1 and activator protein 1 (AP-1) transcription
factors were found to be responsible for XOD upregulation.
Importantly, mTOR, a major myeloid cell translation regulator was
found to be crucial for XOD activation as well. p38 MAP kinase
appeared critical for XOD activation during the biological responses
of human myeloid leukaemia cells triggered through plasma mem-
brane-associated - but not endosomal - TLRs. Specific inhibition of
XOD by allopurinol and sodium tungstate led to an increase in
intracellular AMP levels triggering the downregulation of mTOR
activation by phosphorylation of its T2446 residue. Our results sug-
gest that XOD is important for maintaining intracellular AMP levels
during the biological responses of human myeloid leukaemia cells.
This is critical for activation of the mTOR pathway required for the
biological responses of human myeloid cells. XOD appears, there-
fore, to be both an upstream regulator as well as a downstream target
of the mTOR pathway.
Results
TLR ligands and SCF induce XOD activation, production of UA
and S2448 mTOR phosphorylation. THP-1 human myeloid leuk-
aemia cells expressing TLRs 2, 4, 7 and 8 as well as the pro-leukaemic
SCF/Kit receptor7,8,10,14 were used for the experiments. Relative XOD
expression was assessed by Western blotting (a full membrane is
presented in Supplementary Figure 1) and the relative activity of
the enzyme was analysed as outlined in the Materials and
Methods. We observed that monocytic THP-1 cells expressed detec-
table amounts of XOD which were increased upon PMA-induced
differentiation (24 h of exposure to 100 nM PMA, Figure 1). LAD2
mast cells expressed higher levels of XOD as did MCF-7 epithelial
human breast cancer cells (Figure 1). Mouse liver homogenates were
used as a positive control, since cells of this organ are known to
express the highest levels of XOD15. The obtained results were
consistent with those reported in the literature5,15. Since monocytes
are majorly involved in innate immune responses and remain SCF-
dependent upon malignant transformation, we used non-differen-
tiated THP-1 cells for further experiments7.
We exposed THP-1 cells to 1 mg/ml lipopolysaccharide (LPS,
TLR4 ligand), 1 mg/ml peptidoglycan (PGN, TLR2 ligand), 0.1 mg/
ml R848 (TLR7/8 ligand) as well as 0.1 mg/ml SCF for different
periods of time. XOD activity was assessed using two methods
(one based on the UA detection and another one based on the mea-
surement of XOD-produced hydrogen peroxide, see Materials and
Methods). We also analysed intracellular UA concentrations and
phospho-S2448 mTOR. We found that XOD activity and UA levels
were significantly increased by all the stimuli used. This was in line
with a significant increase in mTOR S2448 phosphorylation
(Figure 2).
Ligand-induced TLR2, 4, 7/8 and Kit-mediated XOD activation
depends on HIF-1 and AP-1 transcription complexes and mTOR.
To assess the role of the HIF-1 transcription complex in XOD
activation we used normal and HIF-1a knockdown THP-1 cells
(the alpha subunit of HIF-1 is an inducible one which acts as a
limiting factor of HIF-1 activity)16. Cells were exposed to 1 mg/ml
LPS, 1 mg/ml PGN, 0.1 mg/ml R848 as well as 0.1 mg/ml SCF for 4 h
followed by detection of intracellular XOD protein levels and
catalytic activity (Figure 3A). We found that treatment of the cells
with all the above stimuli did not significantly upregulate XOD
protein levels but significantly increased its activity. HIF-1a
knockdown THP-1 cells expressed lower levels of XOD and its
activity was significantly affected (Figure 3A). Successful HIF-1a
silencing was controlled by qRT-PCR (see Supplementary Figure 4).
Pre-treatment of THP-1 cells for 1 h with 1 mMAP-1 inhibitor SR
11302 (Tocris) followed by 4 h of treatments with LPS, PGN, R848
and SCF, as shown in Figure 3B, significantly reduced XOD express-
ion and, as a result, dramatically reduced its catalytic activity
(Figure 3B). The observed downregulatory effect was stronger
compared to HIF-1a knockdown, which confirms previous findings
Figure 1 | XOD expression levels and relative activity in different cell
types.XOD protein levels were detected in non-differentiated THP-1 cells,
differentiated THP-1 cells (following 2h exposure to 100 nM PMA),
primary human basophils, LAD2mast cells and mouse liver homogenates.
Relative XOD activity was also measured as outlined in Materials and
Methods. Western blot data show one representative experiment of three
that produced similar results and were quantitatively analysed. Cropped
blots are used. Full-length blots are presented in Supplementary Figure 1.
Other quantitative data are shown as mean values 6 S.D. of at least three
independent experiments (n53).
www.nature.com/scientificreports
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suggesting the presence of more AP-1 responsive elements than
hypoxia (HIF-1) responsive elements1.
We next assessed whether mTOR kinase, which acts as a key
regulator of translation during myeloid cell responses, could also
influence XOD activity, especially under conditions when HIF-1 is
active. Our previous observations demonstrated that downregula-
tion of mTOR during myeloid cell biological reactions reduces
HIF-1 activity10,16. From the experiments above, and previous obser-
vations, we know that HIF-1 is involved in XOD activation. We
therefore pre-treated the cells with 30 mM LY294002 (phosphatidy-
linositol-3 kinase, PI-3K, inhibitor) together with or without 50 mM
CoCl2 (a classic mTOR-independent HIF-1 activator)8,16 for 1 h fol-
lowed by 4 h of exposure to 1 mg/ml PGN. We used LY294002 and
not rapamycin since we found that rapamycin directly activates
purified bovine XOD with the Ka 5 2.36 mM (Supplementary figure
6A and Supplementary table 1). PI-3K is the upstream kinase for
mTOR which is crucial for mTOR activation during TLR and SCF/
Kit-mediated responses ofmyeloid cells. In the described experiment
we measured XOD activity, phospho-S2448 mTOR and HIF-1
DNA-binding activity. We found that downregulation of mTOR is
associated with PGN-induced XOD activation regardless of HIF-1
status (Figure 3C).
The role of the p38MAP kinase pathway in XOD activation during
human myeloid cell activation. Previous studies suggested a possible
role for p38 MAP kinase in XOD activation1,17 and we next set out to
provide definitive evidence to support this notion. First of all, we
exposed THP-1 cells to 1 mg/ml LPS, 1 mg/ml PGN, 0.1 mg/ml R848
as well as 0.1 mg/ml SCF for 4 h followed by Western blot analysis of
p38 MAP kinase phosphorylation and total protein amount of the
kinase. We found that all the stimuli, especially LPS and SCF, induced
p38 MAP kinase phosphorylation, however, R848 was the weakest
inducer (Figure 4A), which is consistent with our previous
observations on the functional role of p38 MAP kinase in different
types of TLR-mediated responses8,14. We then investigated the role of
p38 MAP kinase in LPS (ligand of the plasma membrane-associated
receptor) and R848 (ligand of the endosomal receptor) mediated
responses. For this purpose, THP-1 cells were pre-treated for 1 h
with 1 mM SB203580 (a p38 MAP kinase inhibitor) followed by a 4
or 24 h exposure to 1 mg/ml LPS or 0.1 mg/ml R848. We found that
p38MAP kinase was involved in LPS-induced XOD activation but not
involved in the R848-induced response (Figure 4 B and C), which is in
line with our previous observations for other signalling processes8,14.
Since it has been proposed that p38 MAP kinase might be directly
phosphorylating XOD we investigated whether additional phos-
phorylation of this enzyme is crucial for the investigated myeloid cell
responses. THP-1 cells were exposed for 4 h to 1 mg/ml LPS, 1 mg/ml
PGN, 0.1 mg/ml R848 or 0.1 mg/ml SCF followed by cell lysis and a
1 h exposure to alkaline phosphatase. XOD activity was then ana-
lysed. Treatment with alkaline phosphatase did not affect ligand-
induced XOD activation (Figure 5A). We then analysed whether
phosphate groups are crucial for the catalytic activity of purified
bovine XOD.We exposed purified bovine XOD to alkaline phospha-
tase and found that this treatment did not change XOD catalytic
activity (Figure 5B).
Figure 2 | LPS, PGN, R848 and SCF induce XOD activation and phosphorylation of S2448 mTOR in a time-dependent manner. THP-1 cells were
exposed to 1 mg/ml LPS, 1 mg/ml PGN, 0.1 mg/ml R848 as well as 0.1 mg/ml SCF for different periods of time. XOD activity, intracellular UA levels and
S2448 mTOR phosphorylation were analysed as described in Materials and Methods. Results are shown as mean values 6 S.D. of at least three
independent experiments (n53–5).
www.nature.com/scientificreports
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Figure 3 | HIF-1, AP-1 and mTOR play a role in maintaining XOD activity during the biological responses of THP-1 myeloid cells. (A) Normal
and HIF-1a knockdown THP-1 cells were exposed to 1 mg/ml LPS, 1 mg/ml PGN, 0.1 mg/ml R848 as well as 0.1 mg/ml SCF for 4 h followed by Western
blot analysis of XOD protein levels and activity assay. (B) THP-1 cells were exposed to 1 mg/ml LPS, 1 mg/ml PGN, 0.1 mg/ml R848 as well as 0.1 mg/ml
SCF for 4 h with or without 1 h pre-treatment with 1 mMSR11302 (AP-1 inhibitor). Approximately 90 mg protein was loaded onto the gel (in order to be
able to visualise XOD in all samples, since the AP-1 inhibitor causes a strong downregulation in XODprotein levels). (C) THP-1 cells were exposed for 4 h
to 1 mg/ml PGN (a highly efficacious mTOR activator) with or without 1 h pre-treatment with 10 mM Rapamycin (mTOR inhibitor). In some cases,
50 mM cobalt chloride was added to maintain high HIF-1 activity. XOD activity, phospho-S2448 mTOR and HIF-1 DNA-binding activity (DBA) were
measured as described in Materials and Methods. Western blot data show one representative experiment of three that gave similar results and were
quantitatively analysed. Cropped blots are used. Full-length blots are presented in Supplementary Figures 2 and 3. Other quantitative data are shown as
mean values 6 S.D. of at least three independent experiments; (n53–4) * – p , 0.01 vs. control; a - p , 0.01 vs. corresponding treatment.
Figure 4 | The role of p38 MAP kinase in XOD activation in THP-1 myeloid cells. (A) THP-1 cells were exposed to 1 mg/ml LPS, 1 mg/ml PGN,
0.1 mg/ml R848 as well as 0.1 mg/ml SCF for 4 h followed by Western blot analysis of phospho-p38 MAP kinase versus total p38 MAP kinase. Cropped
blots are used. Full-length blots are presented in Supplementary Figure 5. (B) THP-1 cells were exposed for 4 or 24 h to 1 mg/ml LPS ((B) the strongest p38
MAP kinase inducer) or 0.1 mg/ml R848 ((C) the weakest p38 MAP kinase activator) with or without 1 h pre-treatment with 1 mM SB203580 (p38
MAP kinase inhibitor). XOD activity was analysed as described in Materials and Methods. Results are shown as mean values 6 S.D. of at least three
independent experiments; (n53–6) * – p , 0.01 vs. control.
www.nature.com/scientificreports
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Finally, we investigated whether XOD contains phosphate groups
at all. For this purpose we quantified phosphate groups in purified
bovine XOD. We analysed both unmodified protein as well as fol-
lowing 15 min of temperature denaturation (boiling the preparation
at 95uC). We found that the amount of detectable phosphate groups
was significantly higher in the denatured protein suggesting that the
phosphate groups are buried within the XOD structure (Figure 5C).
XOD activity is essential for S2448mTOR phosphorylation during
the biological responses of human myeloid cells. We investigated
whether XOD, as a crucial purine catabolising enzyme, plays a role in
myeloid cell signalling during TLR-mediated and SCF/Kit-induced
responses of human hematopoietic cells of myeloid lineage. We
pre-treated THP-1 cells with 250 mg/ml allopurinol (XOD isosteric
inhibitor, Ki 5 1.82 mM, see Supplementary figure 6A, Supplemen-
tary table 1) followed by exposure to 1 mg/ml LPS, 1 mg/ml PGN,
0.1 mg/ml R848 or 0.1 mg/ml SCF. We then measured XOD activity
and intracellular UA content. Activity of PI-3K and the intracellular
levels of phospho-S2448 mTOR were also analysed. We found that
XOD activity and UA production were induced by all four stimuli.
This was in line with a significant increase in PI-3K activity and S2448
mTOR phosphorylation (Figure 6). Pre-treatment with allopurinol
attenuated XOD activation/UA production. The amount of phospho-
S2448 mTOR but not PI-3K activity was decreased by allopurinol
(Figure 6). It is known that XOD inhibition leads to intracellular
hypoxanthine accumulation3. Hypoxanthine could then be re-cycled
and converted into inosine monophosphate (IMP) and further into
AMP, which allosterically activates AMP kinase (AMPK)7,18. AMPK is
a physiological inhibitor of mTOR which leads to its phosphorylation
at T2446, thus preventing phosphorylation of the S2448 and therefore
mTOR activation. To investigate whether this is indeed the case, we
performed treatments described above and compared the phosphory-
lation of mTOR at S2448 and T2446. We found that allopurinol
decreased ligand-induced S2448 mTOR phosphorylation while signi-
ficantly increasing T2446 phosphorylation (Supplementary figure
7A). To investigate whether specific XOD inhibition increases
intracellular AMP levels we pre-treated the cells for 1 h with
100 mg/ml sodium tungstate (Na2WO4). Tungsten replaces Mo in
the XOD structure, thus attenuating its activity (Ki 5 1.09 mM, see
Supplementary figure 6B and Supplementary table 1). We used
sodium tungstate as an alternative inhibitor, also because we were
interested in measuring intracellular AMP levels (allopurinol is a
hypoxanthine isomer which could possibly affect successful AMP
measurement). Na2WO4 attenuated ligand-induced XOD activation
and significantly increased its T2446 phosphorylation as well as
intracellular AMP levels (Supplementary figure 7B).
To check whether specific induction of XOD activity leads to any
changes in intracellular AMP levels and mTOR phosphorylation we
exposed THP-1 cells for 24 h to 100 mg/ml ammonium molybdate
((NH4)6Mo7O24), which specifically induces post-translational
activation of XOD (since XOD is a molybden-containing enzyme)19.
We found that XOD activity was significantly increased (Supplemen-
tary figure 8). This was in line with a decrease in intracellular AMP
levels. However, no changes in mTOR phosphorylation on S2448 or
T2446 were observed (Supplementary figure 8).
PGN upregulates XOD activity, UA production, and the PI-3K/
mTOR pathway in mouse blood and liver in vivo.We finally asked
whether the responses investigated in our in vitro studies regarding
TLR ligand-induced activation of XOD and the essential role of the
PI-3K/mTOR pathway actually take place in vivo. Six-week-old CD1
male mice (25 6 5 g) were systemically injected with 1 mg/kg PGN
and sampled 4 h post-injection as described in the Materials and
Methods. We found that PGN induced XOD activity in blood cells
and liver. This was in line with increased UA levels in blood plasma
and liver (Figure 7). Moreover, the activity of PI-3K and S2448
mTOR phosphorylation levels in blood cells and liver homoge-
nates of PGN-injected mice were significantly upregulated
compared to the control groups (Figure 7). These results suggest
that the activation of both XOD and PI-3K/mTOR pathway are
induced by TLR ligands in vivo. Furthermore, they are induced not
only in blood cells but also in the liver – where XOD activity is
naturally the highest.
Discussion
Our investigations clearly confirm the hypothesis of involvement of
XOD in controlling signalling networks associated with functioning
of humanmyeloid hematopoietic cells. Previous reports suggested an
upregulation of this purine catabolising enzyme during TLR-
mediated and growth factor/cytokine-induced responses of human
myeloid cells1,7,8,20. Our studies confirmed that XOD activity as well
as UA production is induced in human myeloid leukaemia cells
exposed to ligands of plasma membrane-associated TLRs 2 and 4,
endosomals TLRs 7/8 as well as the SCF/Kit receptor (Figure 2).
Our study showed that the upregulation of XOD was taking place
more on the level of catalytic activity rather than increasing XOD
protein levels, as shown by ourWestern blot analysis (Figure 3 A and
B). It was, however, found that HIF-1 and AP-1 transcription factors
Figure 5 | XOD contains phosphate groups which are buried within its
structure. (A) THP-1 cells were exposed to 1 mg/ml LPS, 1 mg/ml PGN,
0.1 mg/ml R848 as well as 0.1 mg/ml SCF for 4 h followed by XOD activity
measurement with or without 1 h pre-exposure to alkaline phosphatase.
(B) Activity of purified bovine XOD was measured with or without 1 h
pre-exposure to alkaline phosphatase. (C) Phosphate groups were detected
in purified bovine XOD before and after 15 min temperature (95uC)
denaturation. Results are shown as mean values 6 S.D. of at least three
independent experiments; (n53–6) * – p , 0.01 vs. control.
www.nature.com/scientificreports
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are required tomaintain XOD levels inmyeloid leukaemia cells, since
directed attenuation of HIF-1 or AP-1 activity significantly reduced
XOD protein levels as well as its activity in human myeloid cells
regardless of the stimulus employed (Figure 3 A and B).
Importantly, translational control operated by the mTOR complex
appeared to be directly involved in ligand-inducedXOD activation in
human myeloid leukaemia cells (Figure 3C). These results dem-
onstrate that AP-1 and HIF-1 are clearly involved in ligand-induced
XOD upregulation. Recent evidence suggested that LPS, PGN, R848
and SCF induce activation of mTOR, which appears crucial for upre-
gulation of the HIF-1 transcriptional activity16. However, in the pre-
sent study we demonstrate that mTOR influences XOD activation
independently of HIF-1. The activity of HIF-1 was kept at a high level
with the help of cobalt chloride. But this could not restore a rapa-
mycin-dependent decrease in ligand-induced XOD upregulation in
human myeloid leukaemia cells, despite the fact that rapamycin
could directly activate XOD (Supplementary figure 6, Supplemen-
tary table 1).
Further studies demonstrated the importance of p38 MAP kinase
in XOD activation via plasma membrane-associated TLR4 but not
endosomal TLRs 7/8 (Figure 4). This is in line with our recent obser-
vations where p38 MAP kinase was critically involved in stress
adaptation pathways in myeloid cells during LPS/TLR4-induced res-
ponses but not R848/TLRs7/8-dependent events8,14. It is important to
mention that R848 appeared the weakest p38 MAP kinase activator
compared to other stimuli (PGN, LPS and SCF) used. p38 MAP
kinase is more likely to be involved indirectly (for example through
activation of the AP-1 transcription complex)21 because phosphate
groups appeared to be hidden in the XOD structure and could not be
accessed by alkaline phosphatase (Figure 5).
Further studies demonstrated that XOD activation is crucial for
translational control. Specific inhibition of XOD by allopurinol sig-
nificantly reduced ligand-dependent activation of S2448 mTOR
phosphorylation but not PI-3K (Figure 6). This effect most likely
took place due to provoking the recycling of hypoxanthine due to
the inability of XOD to convert it further. Re-use of hypoxanthine
includes its two-stage conversion into AMP (the allosteric activator
of AMP kinase), which inhibits mTOR through phosphorylation of
T2446. Inhibition of XOD led to an increase in intracellular AMP
levels and phospho-T2446 mTORwhich reduced the amounts of the
phospho-S2448 mTOR (Supplementary figure 7). However, the
changes in S2448 phosphorylation of mTOR do not merely result
from XOD activation since specific molybden-dependent induction
of XOD activity has no effect on mTOR phosphorylation in the
absence of TLR or Kit ligands (Supplementary figure 8). Proposed
possible mechanisms underlying XOD activation in human myeloid
cells during their biological responses are summarised in the
Supplementary figure 9.
Activation of both XOD and the PI-3K/mTOR pathway was
observed in blood cells and liver of mice in vivo too (Figure 7),
following injection of mice with 1 mg/kg TLR2 ligand PGN. These
observations provide an in vivo confirmation of the results obtained
Figure 6 | XOD plays a crucial role in S2448 mTOR phosphorylation during the biological responses of THP-1 humanmyeloid cells. THP-1 cells were
exposed to 1 mg/ml LPS, 1 mg/ml PGN, 0.1 mg/ml R848 as well as 0.1 mg/ml SCF for indicated periods of time with or without 1 h pre-treatment with
250 mg/ml allopurinol. XOD activity, intracellular UA levels, PI-3K activity were measured as outlined in Materials and Methods. Results are shown as
mean values 6 S.D. of at least three independent experiments; (n53–5) * – p , 0.01 vs. control.
www.nature.com/scientificreports
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in vitro, at least to a certain extent. Unlike humans, however, mice are
capable of degrading UA into allantoin, UA levels in these animals
are quite high so that this compound can still act as a ‘‘danger
signal’’8,22,23.
Taken together, our results demonstrate for the first time that
XOD is not just activated in human myeloid cells by pro-inflammat-
ory stimuli/SCF but also plays an important role in maintaining
mTOR-dependent translational control during biological responses
of these cells. These findings open the new route in myeloid cell,
inflammation and leukaemia research, since XOD can now be con-
sidered for investigation as a potential target for curing autoimmune
disease and to relief undesired inflammatory reactions.
Methods
Materials, cells (THP-1, MCF-7, LAD224 and primary human basophils) and animals
(mice) used in the work are described in the Supplementary information.
Animal experiments were performed following approval by the Institutional
Animal Committee and handled in accordance with the Animals (Scientific
Procedures) Act 1986 and Helsinki Declaration.
Transfer ofHIF-1a siRNA intoTHP-1 cells.We employed aHIF-1a-specific siRNA
target sequence (ugu gag uuc gca ucu uga u dtdt) which was localised at position 146
bases downstream of the HIF-1a start codon6,7. Transfection into THP-1 cells was
performed using DOTAP reagent according to the manufacturer’s protocol.
Successful silencing of HIF-1a was controlled by quantitative real-time PCR (qRT-
PCR). Total RNA was isolated using a GenEluteTM mammalian total RNA miniprep
kit, followed by a HIF-1a mRNA reverse transcriptase–polymerase chain reaction
(RT-PCR) in accordance with the manufacturer’s protocols after which qRT-PCR
was performed. Primer selection was as follows: HIF-1a, 59-CTCAAAGTCGGAC-
AGCCTCA-39, 59-CCCTGCAGTAGGTTTCTGCT-39 actin, 59-TGACGGGGT-
CAC-CCACACTGTGCCCATCTA-39, 59-CTAGAAGCATTTGCGGTCGACGA-
TGGAGGG-397. Reactions were performed using a LightCyclerH 480 real-time PCR
system and respective SYBR Green I Master kit (Roche, Burgess Hill, UK). Analysis
was carried out according to the manufacturer’s protocol. Values representing HIF-
1a mRNA levels were normalised against those of actin7. Corresponding random
siRNA (uac acc guu agc aga cac c dtdt) had no effect on the studied processes7.
Detection of XOD activity and UA levels. XOD activity was detected
spectrophotometrically using twomethods4,7. One was based on the ability of XOD to
convert xanthine into UA, which was quantified spectrophotometrically (see Figure 2
for the reaction). 50 ml of borate buffer (0.2 M boric acid mixed with 0.05 M sodium
tetraborate), pH 8.2 (XOD pH optimum) was mixed with 50 ml of 2 mM xanthine
(xanthine was initially dissolved in a minimal volume of 0.01 M NaOH and brought
to the desired volume and the pH adjusted to 8.2). 50 ml of cell lysate (or tissue
homogenate) was added and samples were then incubated for 60–120 min at 40uC
(optimum temperature for XOD activity). Proteins were then precipitated using
0.35 M H2SO4 and 0.3 M sodium tungstate solution. This was followed by detection
of UA using a phosphotungstate assay: alkaline conditions were generated using a
0.95 M sodium carbonate solution. Phosphotungstate reagent was prepared by
mixing 40 g of sodium tungstate and 300 ml of bidistilled deionised water. 32 ml of
concentrated phosphoric acid (15.2 M) was added and the mixture was then boiled
for 2 h before cooling to room temperature. The volume was adjusted to 1 l and 32 g
of lithium sulphate was dissolved in the reagent. The phosphotungstate reagent was
then stored in a dark bottle at 4uC. UA reduces phosphotungstate reagent forming a
steady blue colour (the absorbance was analysed at 650 nm). The amount of UA was
calculated using a calibration curve obtained from the analysis of standard UA
solutions (concentration range – 6.25–1000 mM). Control samples (blank) did not
contain xanthine (since xanthine does not react with phosphotungstate reagent at all
but cell lysate/tissue homogenate could contain traces of uric acid). XOD activity was
expressed in nmol UA produced per 1 min permg protein. Controls were normalised
and expressed as 100%. XOD activities in other samples were expressed as % control.
The other assay was based on the detection of hydrogen peroxide produced by
XOD after converting xanthine into UA (see Figure 2 for the reaction) as described
previously4,25. 60 ml of 0.1 M Tris containing 40 mg/l horseradish peroxidase (HRP)
buffer (pH 7.5 – this pH is perfectly suitable for both XOD and HRP as well as for
quenching reactions) were mixed with 20 ml 2 mM xanthine (see above) and 10 ml of
ortho-phenylendiamine water solution. Reactions were started by adding 20 ml of
sample (the amount could be increased to 50 ml in the case of weak activity). Control
samples (blank) did not contain xanthine. Samples were incubated for 30 min at 40uC
followed by termination of the reaction with 100 ml of 1.88 MH2SO4 solution. H2O2
standards were analysed to calculate XOD activity (concentrations – 0.1–100 nmol/
ml). The absorbance was measured at 492 nm. XOD activity was expressed in nmol
H2O2 produced per 1 min per mg protein. Controls were normalised as 100%. XOD
activities in other samples were expressed as % control.
UA levels were analysed by colorimetric assay using phosphotungstate reagent as
described above24.
Western blot analysis. Intracellular XOD protein as well as phospho-p38/total p38
MAP kinase levels were determined by Western blot analysis and compared to b-
actin to assess equal loading, as we previously reported10. When analysing relative
XOD expression in different cell types and p38 MAP kinase levels we loaded 50 mg
protein per well in SDS PAGE.When analysing XODprotein levels in THP-1myeloid
cells, 50–100 mg protein per well was loaded. Li-Cor (Lincoln, Nebraska USA)
secondary antibodies (conjugated with fluorescent dyes) were used according to the
manufacturer’s protocol in order to visualise the proteins of interest in a Li-Cor
Odyssey imaging system. Using Odyssey software, Western blot data were subjected
to quantitative analysis and values were normalised against respective b-actin bands.
Detection of phospho-S2448 and phospho-T2446 mTOR in cell lysates by ELISA.
ELISA was employed to analyse S2448 or T2446 phosphorylation of mTOR as we
previously described7. Briefly, plates coated with mouse anti-mTOR antibody and
blocked with 1% BSAwere incubated with cell lysates at room temperature for at least
2 h with constant agitation. Plates were then washed with TBST (10 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 0.05% Tween-20) buffer and anti-phospho-S2448 (or anti-
phospho-T2446) mTOR antibody was added followed by a 2 h incubation at room
temperature (with agitation). Plate were then washed 5 times with TBST buffer and
incubated with 151000 HRP-labelled goat anti-rabbit IgG in TBST buffer for at least
2 h. After extensive washing with TBST, bound secondary antibodies were detected
by the peroxidase reaction (ortho-phenylenediamine/H2O2) as described.
Determination ofHIF-1DNA-binding activity.HIF-1DNA-binding activity (HIF-
1 DBA) was measured using the method we described recently7. Briefly, 96-well
MaxisorpTM microtitre plates were coated with streptavidin and blocked with BSA. 2
pmol/well biotinylated 2HRE-containing oligonucleotide were immobilised by 1 h
incubation of the plates at room temperature. Plates were then washed 5 times with
Figure 7 | PGN activates XOD and PI-3K/mTOR pathway in vivo.
Twenty (four groups of five animals) six week old male CD1 mice were
used as outlined in Materials and Methods. Blood was collected and the
liver was isolated and homogenised. XODactivity, phospho-S2448mTOR,
and PI-3K activity were measured in blood cells and liver. UA levels were
detected in the blood plasma (A) and liver (B). Quantitative data are mean
values 6 S.D. (n55); *p , 0.05 vs. control.
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TBST buffer followed by 1 h incubation with 20 ml/well of cell lysate at room
temperature. After washing the plates 5 times with TBST buffer mouse anti-HIF-1a
antibody (151000 in TBS plus 2% BSA) was added and plates were incubated for 1 h
before a further washing cycle. 151000 HRP-labelled rabbit anti-mouse IgG in TBST
buffer was then added to the wells and, after extensive washing with TBST, bound
secondary antibodies were detected by the peroxidase reaction (ortho-
phenylenediamine/H2O2).
Detection of PI-3K activity, AMP levels and phosphate groups. PI-3K activity was
detected based on the previously described approach26. Briefly, cell lysates were each
incubated with 30 ml 0.1 mg/ml substrate (PI-4,5-diphosphate – the emulsion was
prepared using bidistilled water; sonication for 1 hour in a water bath sonicator is
recommended) in kinase assay buffer. The latter was prepared from 20 mMTris (pH
7.5), 100 mMNaCl, 0.5 mM EDTA, 8 mMMgCl2 and 40 mMATP in a total volume
of 100 ml at 37uC with constant agitation. Reactions were stopped by adding 1 ml of
mixture hexane/isopropanol (1357, v5v) and 0.2 ml of a mixture of 2 MKCl/HClconc
(850.25, v5v). Samples were vortexed and organic phases were washed with HCl
(0.5 ml;0.1 M). This was followed by detection of phosphate groups using
molybdenum reagent25,27 containing 2 parts of 25 mM (NH4)6Mo7O24, 5 parts of
H2SO4 (140 ml of H2SO4 conc was diluted to 900 ml with bidistilled water), 2 parts of
0.3 M ascorbic acid and 1 part of 2 mM potassium antimonyl-tartrate25,26. In case of
very high or low absorbance, the product (PI-3,4,5-triphosphate) should be separated
by thin-layer chromatography (TCL) using silica gel TCL plates (chromatographic
mixture of 2 M acetic acid/isopropanol (152, v5v) has to be applied) and detected
using molybdenum reagent. The values obtained in the control samples of each
experiment per 1 mg protein were counted as 100% of the PI-3K activity. Other
values were normalised and expressed as % control.
Intracellular AMP levels were detected based on the use of a commercial Promega
AMP luminometric assay kit according to the manufacturer’s protocols.
Phosphate groups in the purified protein were detected usingmolybdenum reagent
as described above.
Statistical analysis. Each experiment was performed at least three times and
statistical analysis was conducted using a sample distribution analysis followed by a
two-tailed Student’s t test. Statistical probabilities (p) were expressed as *, where
p,0.01.
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